Key facts
- It has raised $44.2M across 5 recorded rounds; the latest was Seed Round ($3.5M) in Aug 2024.
- Notable investors include Arboretum Ventures, Baird Capital, Global Health Investment Corporation, LYZZ Capital.
- Jumpcode Genomics has filed 5 Form Ds with the SEC since 2018, most recently Aug 2024 ($3.5M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Jumpcode Genomics
Funding rounds
5 roundsAbout Jumpcode Genomics
Developer of a genome technology designed for decoding and applying new information to the world's problems. The company's technology depletes unwanted nucleic acid molecules from sequencing libraries, fitting seamlessly within standard workflows with the commercially available library preparation services, enabling researchers to improve detection sensitivity, remove bias, reduce cost, and simplify workflow.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2016
- Employees
- 19
- Website
- jumpcodegenomics.com/
- Ownership
- Privately Held (backing)
Jumpcode Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jumpcode Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jumpcode Genomics in its N-PORT filings yet. We sweep new filings monthly.